Tranquis Therapeutics, Inc.

Tranquis Therapeutics, Inc. is a biotechnology company focused on developing advanced therapeutics to address unmet medical needs, specializing in innovative solutions for mental health and neurodegenerative diseases. Tranquis Therapeutics, Inc. was founded in 2016 and is headquartered in San Mateo, US.

The company is dedicated to creating novel therapeutic options for mental health and neurodegenerative conditions. Tranquis has secured USD 30 mn in Series A funding, successfully closing its most recent deal on July 9, 2020, with investments from Remiges Ventures, SR One, Vivo Capital, Hillsborough Venture, and Correlation Ventures. Tranquis Therapeutics, Inc. specializes in developing biologically-based treatments aimed at improving mental health and addressing neurodegenerative conditions.

Their focus is on translating groundbreaking scientific discoveries into effective therapies, ensuring the delivery of impactful health solutions to patients and healthcare providers. The revenue model for Tranquis Therapeutics is primarily focused on the development and commercialization of its therapeutic products, with potential future income derived from partnerships, licensing agreements, and sales of their innovative treatments as they progress through clinical development. Tranquis Therapeutics plans to leverage the USD 30 mn raised in its Series A funding round to advance its pipeline of therapeutics targeting mental health and neurodegenerative diseases. The company aims to expand its research and development efforts, with plans to enter new markets in North America and Europe by 2023.

The funding will also support the clinical trials necessary for launching upcoming product candidates.